Tocagen (NASDAQ:TOCA) Upgraded to Buy at Zacks Investment Research
Zacks Investment Research upgraded shares of Tocagen (NASDAQ:TOCA) from a hold rating to a buy rating in a report published on Thursday morning, Zacks.com reports. Zacks Investment Research currently has $4.25 price objective on the stock.
According to Zacks, “Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company which focuses on retroviral gene therapy platforms. The company’s lead product candidate consists of Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma, a disease with a significant unmet medical need. Tocagen, Inc. is based in San Diego, United States. “
TOCA has been the subject of several other research reports. Robert W. Baird downgraded Tocagen from an outperform rating to a neutral rating in a report on Thursday. Leerink Swann set a $5.00 price target on Tocagen and gave the company a hold rating in a report on Wednesday, May 22nd. Cantor Fitzgerald downgraded Tocagen from an overweight rating to a neutral rating in a report on Thursday. Citigroup assumed coverage on Tocagen in a report on Thursday, May 30th. They set a buy rating for the company. Finally, ValuEngine raised Tocagen from a hold rating to a buy rating in a report on Thursday, August 1st. Nine research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of Hold and a consensus target price of $12.95.
Tocagen (NASDAQ:TOCA) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.04. Tocagen had a negative return on equity of 115.81% and a negative net margin of 300.42%. The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.50 million. On average, research analysts anticipate that Tocagen will post -2.67 earnings per share for the current fiscal year.
Hedge funds have recently bought and sold shares of the business. BNP Paribas Arbitrage SA increased its position in Tocagen by 72,350.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 4,347 shares of the company’s stock worth $47,000 after buying an additional 4,341 shares during the period. Creative Planning bought a new position in Tocagen during the 1st quarter worth $117,000. Parametric Portfolio Associates LLC bought a new position in Tocagen during the 2nd quarter worth $75,000. Bank of America Corp DE increased its position in Tocagen by 28.6% during the 4th quarter. Bank of America Corp DE now owns 14,584 shares of the company’s stock worth $120,000 after buying an additional 3,240 shares during the period. Finally, A.R.T. Advisors LLC bought a new position in Tocagen during the 2nd quarter worth $114,000. Hedge funds and other institutional investors own 35.43% of the company’s stock.
Tocagen Company Profile
Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.
Recommended Story: Systematic Risk
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.